Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study

References

• Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83.
   PubMed Web of Science ®Google Scholar
• Reddy P, Boci K, Charbonneau C. The epidemiologic, health-related quality of life, and economic burden of gastrointestinal stromal tumours. J Clin Pharm Ther 2007;32:557-65
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008;112:608-15
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force Report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010;8 (Suppl 2):S1-41; quiz S2-4
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Hatrmann J, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol 2011;29 (Suppl):Abstract LBA1
   Google Scholar
• Essat M, Cooper K. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. Int J Cancer 2011;128:2202-14
   PubMed Web of Science ®Google Scholar
• Reynoso D, Trent JC. Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments. Curr Opin Oncol;2010;22:330-5
   PubMed Web of Science ®Google Scholar
• Eisenberg BL, Smith KD. Adjuvant and neoadjuvant therapy for primary GIST. Cancer Chemother Pharmacol 2011;67(Suppl 1):S3-8
   PubMed Web of Science ®Google Scholar
• Pisters PW, Blanke CD, von Mehren M, et al. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Ann Oncol 2011;22:2523-9
   PubMed Web of Science ®Google Scholar
• PharMetrics® Integrated Database. 2011 [cited December 8, 2011]; Available from: http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=6d7660b6f5aa0210VgnVCM100000ed152ca2RCRD&vgnextchannel=bc42650204850210VgnVCM100000ed152ca2RCRD&vgnextfmt=default
   Google Scholar
• FDA/Center for Drug Evaluation and Research. National Drug Code Directory, 2011
   Google Scholar
• ICD9.chrisendres.com. 2011 [cited December 8, 2011]; Available from: http://icd9cm.chrisendres.com/index.php
   Google Scholar
• CPT-4 and HCPCS Codes Subject to CLIA Edits. 2011 [cited December 1, 2011]; Available from: https://www.cms.gov/CLIA/downloads/Subject.to.CLIA.pdf
   Google Scholar
• Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4
   PubMed Web of Science ®Google Scholar
• Hatoum H, Lin SJ, Trent J, et al. Clinical outcomes, numbers needed to treat (NNT), and resource use in gastrointestinal stromal tumors (GIST) patients treated with adjuvant imatinib: results of a population-based cohort study. Annual Meeting of the Academy of Managed Care Pharmacy; 2011 October 19-21, 2011 Atlanta, GA, 2011
   Google Scholar
• Halpern R, Barghout V, Zarotsky V, et al. Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors. J Clin Outcomes Manage 2009;16:215-23
   Google Scholar
• Rubin JL, Sanon M, Taylor DC, et al. Epidemiology, survival, and costs of localized gastrointestinal stromal tumors. Int J Gen Med 2011;4:121-30
   PubMedGoogle Scholar
• Pawlik T, Vauthey J, Abdalla E, et al. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006;141:537-44
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007;14:14-24
   PubMed Web of Science ®Google Scholar